Canaccord raised the firm’s price target on Palvella Therapeutics (PVLA) to $90 from $66 and keeps a Buy rating on the shares. The firm noted the company recently announced the 3rd indication for QTORIN rapamycin: clinically significant angiokeratomas which is another rare, chronically debilitating skin disease with no approved therapies. They came away encouraged by the potential of QTORIN rapa to treat this new indication given similarities with mLM and strong scientific rationale and as such, are adding this new opportunity to their model.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Positive Buy Rating for Palvella Therapeutics Driven by Promising CVM Treatment and Market Potential
- Palvella Therapeutics price target raised to $120 from $70 at Cantor Fitzgerald
- Palvella Therapeutics price target raised to $80 from $56 at Truist
- Palvella Therapeutics price target raised to $95 from $75 at H.C. Wainwright
- Palvella Expands QTORIN Gel Program for Rare Disease